An integrated approach based on FDA adverse event reporting system, network pharmacology, molecular docking, and molecular dynamics simulation analysis to study the cardiac adverse reactions and mechanism of action of osimertinib
This study clarifies osimertinib-induced CAR mechanisms involving multi-target interactions and pathway dysregulation, aiding clinical safety and future research.
Authors
- Yongqing Wen
- Hong Liu (ORCID: https://orcid.org/0000-0001-6040-5323)
- Xu Ma (ORCID: https://orcid.org/0000-0002-2015-2891)
- Wenjuan Wang (ORCID: https://orcid.org/0000-0001-9180-2823)
- Yanhua Zhang (ORCID: https://orcid.org/0009-0002-4396-4603)
Institutions
- Peking University (CN)
- Peking University Cancer Hospital (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-06-09
- DOI
- https://doi.org/10.3389/fphar.2025.1619517
- Citations
- 3
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 4.56
Funders
- Peking University